BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 25966834)

  • 1. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors - March 2008 update.
    Fonseca JE; Lucas H; Canhão H; Duarte R; Santos MJ; Villar M; Faustino A; Raymundo E
    Rev Port Pneumol; 2008; 14(2):271-83. PubMed ID: 25966834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors: March 2008 update.
    Fonseca JE; Lucas H; Canhão H; Duarte R; Santos MJ; Villar M; Faustino A; Raymundo E
    Acta Reumatol Port; 2008; 33(1):77-85. PubMed ID: 18344925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases for candidates for therapy with tumor necrosis factor alpha inhibitors--March 2008 update.
    Eurico Fonseca J; Lucas H; Canhão H; Duarte R; José Santos M; Villar M; Faustino A; Raymundo E;
    Rev Port Pneumol; 2008; 14(2):271-83. PubMed ID: 18564448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recommendations for the diagnosis and treatment of latent and active tuberculosis in patients with inflammatory joint diseases treated with tumour necrosis factor alpha inhibitors].
    Fonseca JE; Lucas H; Canhão H; Duarte R; Santos MJ; Villar M; Faustino A; Raymundo E; ;
    Acta Reumatol Port; 2006; 31(3):237-45. PubMed ID: 17094335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Guidelines for the diagnosis and treatment of latent tuberculosis infection and active tuberculosis in patients with inflammatory joint diseases proposed for treatment with tumour necrosis factor alpha antagonist drugs].
    Fonseca JE; Lucas H; Canhão H; Duarte R; Santos MJ; Villar M; Faustino A; Raymundo E; ;
    Rev Port Pneumol; 2006; 12(5):603-13. PubMed ID: 17117328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Update of the guidelines of the Israeli Association of Rheumatology for the prevention of tuberculosis in patients treated with TNF-alpha blockers].
    Balbir-Gurman A; Lidgi M; Elkayam O
    Harefuah; 2014 Jun; 153(6):359-61, 366. PubMed ID: 25095612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.
    Kim HC; Jo KW; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Shim TS
    Scand J Infect Dis; 2014 Nov; 46(11):763-9. PubMed ID: 25195652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biologics and mycobacterial diseases].
    Tsuyuguchi K; Matsumoto T
    Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
    Gómez-Reino JJ; Carmona L; Angel Descalzo M;
    Arthritis Rheum; 2007 Jun; 57(5):756-61. PubMed ID: 17530674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined use of a TST and the T-SPOT®.TB assay for latent tuberculosis infection diagnosis before anti-TNF-α treatment.
    Jung YJ; Lyu J; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee KH; Lee SD; Kim WS; Kim DS; Shim TS
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1300-6. PubMed ID: 22863375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Guidelines of the Israeli association of rheumatology for the prevention of tuberculosis in patients treated with TNF-alpha blockers].
    Elkayam O; Balbir-Gurman A; Lidgi M; Rahav G; Weiler-Ravel D
    Harefuah; 2007 Mar; 146(3):235-7, 244. PubMed ID: 17460934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis.
    Kwon M; Sung M; Kwon YJ; Song YG; Lee SW; Park MC; Park YB; Lee SK; Song JJ
    J Clin Rheumatol; 2014 Mar; 20(2):68-73. PubMed ID: 24561408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for latent tuberculosis in anti-TNF-α candidate patients in a high tuberculosis incidence setting.
    Saidenberg-Kermanac'h N; Semerano L; Naccache JM; Brauner M; Falgarone G; Dumont-Fischer D; Guillot X; Valeyre D; Boissier MC
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1307-14. PubMed ID: 22863801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis.
    Sauzullo I; Mengoni F; Marocco R; Potenza C; Skroza N; Tieghi T; Lichtner M; Vullo V; Mastroianni CM
    Br J Dermatol; 2013 Nov; 169(5):1133-40. PubMed ID: 23909256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LTBI screening in rheumatoid arthritis patients prior to anti-TNF treatment in an endemic area.
    Bonfiglioli KR; Ribeiro AC; Moraes JC; Saad CG; Souza FH; Calich AL; Bonfa E; Laurindo IM
    Int J Tuberc Lung Dis; 2014 Aug; 18(8):905-11. PubMed ID: 25199003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The clinical application of quantiferon TB-2G: its usefulness and limitations].
    Sato S; Nagai H
    Kekkaku; 2011 Feb; 86(2):101-12. PubMed ID: 21404654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations.
    Iannone F; Cantini F; Lapadula G
    J Rheumatol Suppl; 2014 May; 91():41-6. PubMed ID: 24788999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions.
    Kleinert S; Tony HP; Krueger K; Detert J; Mielke F; Rockwitz K; Schwenke R; Burmester GR; Diel R; Feuchtenberger M; Kneitz C
    Ann Rheum Dis; 2012 Nov; 71(11):1791-5. PubMed ID: 22586160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Quantiferon-TB-Gold in Tube(®) test for detecting latent tuberculosis in patients considered as candidates for anti-TNF therapy in routine clinical practice.
    García-Gasalla M; Fernández-Baca V; Juan-Mas A; Payeras-Cifre A; Cifuentes-Luna C; Taberner-Ferrer R; Riera-Oliver J; Ros-Villamajó I; Navarro-Fernández V; Morey Torrandell C; Gallegos-Alvarez C; Mir-Villadrich I
    Enferm Infecc Microbiol Clin; 2013 Feb; 31(2):76-81. PubMed ID: 22902246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study.
    Garcovich S; Ruggeri A; D'Agostino M; Ardito F; De Simone C; Delogu G; Fadda G
    J Eur Acad Dermatol Venereol; 2012 Dec; 26(12):1572-6. PubMed ID: 21923840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.